We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Medicare for All Could Stifle Drug Innovation, CBO Says
Medicare for All Could Stifle Drug Innovation, CBO Says
Prescription drug costs would likely have a small impact on federal spending under a single-payer system but a national health system might have the unintended consequence of forcing drugmakers to stop taking risks on new medicines, the Congressional Budget Office says in a new analysis released Wednesday.